Effects of Cardiotoxicity Surveillance on Heart Failure Risk During HER2 Targeted Therapy for Breast Cancer
Study design and summary of major findings in a case control study of 53 patients who developed heart failure (HF) during human epidermal growth factor receptor 2 (HER2) targeted therapy and 159 control patients. Adherence to cardiotoxicity surveillance guidelines was suboptimal for both cases and controls and was not associated with lower HF risk. However, a left ventricular ejection fraction (LVEF) <55%, as shown in red, was detected during routine surveillance in 49% of cases (before the development of HF) but only 3% of controls and was associated with increased HF risk. CI = confidence interval; OR = odds ratio.